Latest News and Press Releases

LOS ANGELES, July 10, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced the completion of its initial CAR-T NXC-201 engineering batch at its U.S....

LOS ANGELES, June 26, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering cell therapies targeting oncology and other...

Mr. Borkowski joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical and healthcare industry, including 7 years as Chief Financial Officer of...

Mr. Cooper joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical industry, including 5 years as Chief Financial Officer of BioMarin...

Dr. Coleman joins the Nexcella, Inc. Board of Directors with over a decade of experience as an Independent Director of Johnson & Johnson from 2003-2016Dr. Coleman is President Emerita of the...

Dr. McKinnell joins the Nexcella, Inc. Board of Directors with 35 years of experience at Pfizer, Inc., including 6 years as Chairman and Chief Executive OfficerDr. McKinnell is a former independent...

U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineering batches are the first step in transferring...

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201100% (8/8) overall response rate and 63% (5/8) complete response (MRD 10-5) was demonstrated by...

LOS ANGELES, May 04, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (Nasdaq: IMMX) (“Nexcella”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected for...

Multiple Myeloma 92% was the overall response rate produced by NXC-201 in relapsed/refractory multiple myeloma patients treated at the therapeutic dose of 800 million CAR+T cells in its ongoing phase...